Tyra Biosciences, Inc. (TYRA): Total Assets
$282.61M
As of 2025-12-31
$383.36M
As of 2026-06-30
+2.0%
3-year compound annual growth
+77.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $282.61M | -22.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $363.56M | +61.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $225.86M | -15.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $266.18M | -13.2% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $306.70M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | $16.01M | n/a | 2022-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $282.61M | -22.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $279.93M | +100.9% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $277.57M | -20.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Neurogene Inc. (NGNE) | 2025-12-31 | $288.60M | -14.0% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $276.64M | +30.0% |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗